Generic and brand-name drugmakers are set for a March 25 Supreme Court case in which federal officials argue that drug prices would be reduced without patent settlements. The case "will define how an entire industry does business," Generic Pharmaceutical Association President Ralph Neas said. An unfavorable ruling will be bad for drugmakers, taxpayers and consumers, he said.

Related Summaries